TY - JOUR
T1 - Solubility of lovastatin in a family of six alcohols
T2 - Ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol, and 1-octanol
AU - Nti-Gyabaah, J.
AU - Chmielowski, R.
AU - Chan, V.
AU - Chiew, Y. C.
N1 - Funding Information:
Joseph Nti-Gyabaah would like to acknowledge Ms. Ellen Dahlgren and Ms. Donna Franklin for their help in setting up the equipment used for this work, and appreciates the technical interactions with Dr. David Roush. The authors remain very grateful to Merck Research Laboratories for supporting and funding this research.
PY - 2008/7/9
Y1 - 2008/7/9
N2 - Accurate experimental determination of solubility of active pharmaceutical ingredients (APIs) in solvents and its correlation, for solubility prediction, is essential for rapid design and optimization of isolation, purification, and formulation processes in the pharmaceutical industry. An efficient material-conserving analytical method, with in-line reversed HPLC separation protocol, has been developed to measure equilibrium solubility of lovastatin in ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol, and 1-octanol between 279 and 313 K. Fusion enthalpy ΔHfus, melting point temperature, Tm, and the differential molar heat capacity, ΔCP, were determined by differential scanning calorimetry (DSC) to be 43,136 J/mol, 445.5 K, and 255 J/(mol K), respectively. In order to use the regular solution equation, simplified assumptions have been made concerning ΔCP, specifically, ΔCP = 0, or ΔCP = ΔS. In this study, we examined the extent to which these assumptions influence the magnitude of the ideal solubility of lovastatin, and determined that both assumptions underestimate the ideal solubility of lovastatin. The solubility data was used with the calculated ideal solubility to obtain activity coefficients, which were then fitted to the van't Hoff-like regular solution equation. Examination of the plots indicated that both assumptions give erroneous excess enthalpy of solution, H∞, and hence thermodynamically inconsistent activity coefficients. The order of increasing ideality, or solubility of lovastatin was butanol > 1-propanol > 1-pentanol > 1-hexanol > 1-octanol.
AB - Accurate experimental determination of solubility of active pharmaceutical ingredients (APIs) in solvents and its correlation, for solubility prediction, is essential for rapid design and optimization of isolation, purification, and formulation processes in the pharmaceutical industry. An efficient material-conserving analytical method, with in-line reversed HPLC separation protocol, has been developed to measure equilibrium solubility of lovastatin in ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol, and 1-octanol between 279 and 313 K. Fusion enthalpy ΔHfus, melting point temperature, Tm, and the differential molar heat capacity, ΔCP, were determined by differential scanning calorimetry (DSC) to be 43,136 J/mol, 445.5 K, and 255 J/(mol K), respectively. In order to use the regular solution equation, simplified assumptions have been made concerning ΔCP, specifically, ΔCP = 0, or ΔCP = ΔS. In this study, we examined the extent to which these assumptions influence the magnitude of the ideal solubility of lovastatin, and determined that both assumptions underestimate the ideal solubility of lovastatin. The solubility data was used with the calculated ideal solubility to obtain activity coefficients, which were then fitted to the van't Hoff-like regular solution equation. Examination of the plots indicated that both assumptions give erroneous excess enthalpy of solution, H∞, and hence thermodynamically inconsistent activity coefficients. The order of increasing ideality, or solubility of lovastatin was butanol > 1-propanol > 1-pentanol > 1-hexanol > 1-octanol.
KW - Alcohols
KW - Lovastatin
KW - Pharmaceutical
KW - Solubility
KW - Statins
KW - Temperature
UR - http://www.scopus.com/inward/record.url?scp=44749093033&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2008.03.046
DO - 10.1016/j.ijpharm.2008.03.046
M3 - Article
C2 - 18490118
AN - SCOPUS:44749093033
SN - 0378-5173
VL - 359
SP - 111
EP - 117
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -